G-rich nucleic acids can form non-canonical G-quadruplex structures (G4s) in which four
guanines fold in a planar arrangement through Hoogsteen hydrogen bonds. Although many …

Since the discovery of HIV as the cause for AIDS 30 years ago, major progress has been
made, including the discovery of drugs that now control the disease. Here, we review the …

Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency
virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN …

The development of HIV-1 dual inhibitors is a highly innovative approach aimed at reducing
drug toxic side effects as well as therapeutic costs. HIV-1 integrase (IN) and reverse …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections initiate in the
bronchi of the upper respiratory tract and are able to disseminate to the lower respiratory tract, …

Integrase (IN) is the newest validated target against AIDS and retroviral infections. The
remarkable activity of raltegravir (Isentress®) led to its rapid approval by the FDA in 2007 as the …

A series of antiviral basic quinolinonyl diketo acid derivatives were developed as inhibitors
of HIV-1 IN. Compounds 12d,f,i inhibited HIV-1 IN with IC 50 values below 100 nM for strand …

Objective: In this study, we characterized elvitegravir activity in the context of raltegravir
resistance mutations. Design: Using site-directed mutagenesis, we generated recombinant …

There are currently three HIV-1 integrase (IN) strand transfer inhibitors (INSTIs) approved by
the FDA for the treatment of AIDS. However, the emergence of drug-resistant mutants …

The increasing efficiency of HAART has helped to transform HIV/AIDS into a chronic disease.
Still, resistance and drug–drug interactions warrant the development of new anti-HIV …